VA-DXC-TECHNOLOGY
21.5.2020 15:02:13 CEST | Business Wire | Press release
DXC Technology (NYSE: DXC) today introduced its Corporate Incident Response (CIR) application for ServiceNow to enable organizations like Banco Santander, one of the largest retail and commercial banks in the world, and the Nordex Group, one of the world’s largest wind turbine manufacturers, to quickly and proactively identify, address and manage important non-IT corporate incidents, such as those related to facilities, physical security, and environment, health and safety. The application, built on the ServiceNow platform, allows businesses to reduce their risk profiles and overcome situations before they evolve into companywide crises.
The CIR application provides an end-to-end workflow management solution to manage, track and respond to non-IT-related issues in an efficient, standardized manner.
“In today’s world, business disruptions are inevitable. While operational resilience has been around for years, a change in mindset is required in order to prevent, respond to, recover from, and most importantly, learn from and adapt after crises occur,” said Dan Stoks, vice president, Global ServiceNow Practice, DXC Technology. “The Corporate Incident Response application can work with ServiceNow’s integrated risk management and other workflows to enable organizations to securely manage crisis response workflows and risks to the business.”
Key features of the solution:
- Situation rooms — provide a central point of collaboration for dispersed organizations to orchestrate response teams and plans and monitor and evaluate the overall picture.
- App notifications — provide the ability to send companywide notifications, such as alerts, push notifications, email and SMS to predefined groups as well as external partners and customers.
- 360-degree view — provides the management team with a 360-degree view of where the organization stands on corporate-related incidents, so they can make fact-based decisions that reduce their overall risk profile.
Banco Santander Streamlines Crisis Management Systems with DXC CIR Application
Banco Santander wanted a single platform to manage its global facility and security processes and replace its previous system with a new, digitized platform. Using the DXC CIR application with ServiceNow, Santander streamlined its processes with better-performing facility, security and crisis management systems and improved user experiences for its managers and end users. It also benefited from better insights and greater transparency in its global facility and security services.
“The consolidation of existing and new facility management capabilities to a new platform was a crucial part of our business transformation journey,” said Galo Gilarranz Vicente, Real Estate, General Services and Security, Banco Santander. “DXC’s CIR application has allowed us to reduce costs by rationalizing the global application landscape, standardize our processes and increase employee efficiency with automation.”
The Nordex Group Improves Worker Safety with DXC’s Health, Safety and Environmental Management Business Expertise
The Nordex Group tapped the DXC Health, Safety and Environment Suite (HSE) for ServiceNow, which is part of DXC’s CIR portfolio, to create a safety-driven culture throughout its global operations. With the DXC suite, the Nordex Group experienced a more streamlined process to reduce worker hazards and prevent incidents before they occur.
“Nordex is committed to worker safety, implementing proper processes to prevent and quickly respond to work-related incidents,” said Philipp Marten, program manager, Business Systems, Nordex Group. “With DXC’s HSE solution, we were able to reduce the complexity of our system, streamline reporting and create a safer work environment throughout our global operations.”
DXC is offering this application for free for 120 days to complement and enhance the capabilities of ServiceNow Emergency Response Management applications.
“Operational risk management is a crucial part of how ServiceNow enables resilience for our customers for both IT and non-IT operations,” said David Parsons, senior vice president, Global Alliances and Channel Ecosystem, ServiceNow. “Corporate Incident Response from DXC Technology exemplifies the innovative applications that extend the value of the Now Platform and our Risk and Business Continuity portfolio to serve critical and emerging use cases for joint customers enterprise-wide.”
To learn more and download the CIR for ServiceNow application, click here .
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005190/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
